BusinessWeek provides a reality check on progress in commercial research and development of stem cell based regenerative medicine. "The politicization of this has created a whole field of overnight experts who have no clue what they are talking about. Most of them have never seen an embryonic stem cell." The article makes that case that gains in the market due to the passage of Proposition 71 are largely misguided investor enthusiasm - a closer look is required before taking any of it at face value. Commercialization of medical advances is a long, hard road; there is a way to go yet for even the earliest and most promising stem cell therapies.